A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines

Citation:

Mario Niepel, Marc Hafner, Caitlin E.Mills, Kartik Subramanian, Elizabeth H. Williams, Mirra Chung, Benjamin Gaudio, and Anne Marie Barrett. 7/24/2019. “A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.” Cell Systems, 9, 1, Pp. 35-48. Publisher's Version

Abstract:

Evidence that some high-impact biomedical results cannot be repeated has stimulated interest in practices that generate findable, accessible, interoperable, and reusable (FAIR) data. Multiple papers have identified specific examples of irreproducibility, but practical ways to make data more reproducible have not been widely studied. Here, five research centers in the NIH LINCS Program Consortium investigate the reproducibility of a prototypical perturbational assay: quantifying the responsiveness of cultured cells to anti-cancer drugs. Such assays are important for drug development, studying cellular networks, and patient stratification. While many experimental and computational factors impact intra- and inter-center reproducibility, the factors most difficult to identify and control are those with a strong dependency on biological context. These factors often vary in magnitude with the drug being analyzed and with growth conditions. We provide ways to identify such context-sensitive factors, thereby improving both the theory and practice of reproducible cell-based assays.
Last updated on 01/12/2021